Clinical Research Directory
Browse clinical research sites, groups, and studies.
Hemodialysis.-Induced Hypotension Therapy for End Stage Kidney Disease
Sponsor: Vanderbilt University Medical Center
Summary
Bradykinin is a potent vasodilator that is formed by the activation of the kallikrein-kinin system. We and others have shown that bradykinin increased during hemodialysis; however, the role of bradykinin in dialysis-induced hypotension (DIH) has not been evaluated. Preliminary results from a pilot clinical trial showed that bradykinin B2 receptor blockade with icatibant prevents excessive blood pressure during hemodialysis. Thus, in this study, we will test the overarching hypothesis that blockade plasma kallikrein with lanadelumab would ameliorate the reduction of blood pressure during hemodialysis in patients who are prone to DIH. For this purpose, we will conduct a parallel arm, double-blind placebo-controlled trial, using lanadelumab to evaluate the occurrence of
Official title: Prevention of Dialysis-Induced Hypotension by Inhibiting Plasma Kallikrein
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
28
Start Date
2022-07-27
Completion Date
2026-01-31
Last Updated
2026-01-20
Healthy Volunteers
No
Interventions
Lanadelumab Injection [Takhzyro]
Lanadelumab 300 mg subcutaneous injection
Placebo
Placebo injection
Locations (1)
Vanderbilt University Medical Center
Nashville, Tennessee, United States